Login / Signup

Exploring Odevixibat's efficacy in alagille syndrome: insights from recent clinical trials and IBAT Inhibitor Experiences.

Chaowapong JarasvaraparnMinna RodrigoChristopher HartleyWikrom Karnsakul
Published in: Expert opinion on pharmacotherapy (2024)
Odevixibat or IBAT inhibitor should be considered as a first-line treatment for ALGS to improve pruritis, quality of life and liver-related outcomes including absence of liver transplant, surgical biliary diversion, hepatic decompensation, and death.
Keyphrases
  • clinical trial
  • mental health
  • case report
  • randomized controlled trial
  • robot assisted
  • metabolic syndrome
  • adipose tissue
  • study protocol
  • skeletal muscle
  • double blind
  • insulin resistance